[go: up one dir, main page]

WO2003045990A3 - Interactions proteine-proteine impliquant une signalisation du facteur de croissance transformant $g(b) ou des signaux de transduction d'elements de la famille des facteurs transformants $g(b) - Google Patents

Interactions proteine-proteine impliquant une signalisation du facteur de croissance transformant $g(b) ou des signaux de transduction d'elements de la famille des facteurs transformants $g(b) Download PDF

Info

Publication number
WO2003045990A3
WO2003045990A3 PCT/EP2002/013866 EP0213866W WO03045990A3 WO 2003045990 A3 WO2003045990 A3 WO 2003045990A3 EP 0213866 W EP0213866 W EP 0213866W WO 03045990 A3 WO03045990 A3 WO 03045990A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
growth factor
transforming growth
protein interactions
factor beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/013866
Other languages
English (en)
Other versions
WO2003045990A2 (fr
Inventor
Pierre Legrain
Jean-Michel Gauthier
Frederic Colland
Xavier Jacq
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aton SA
Original Assignee
Hybrigenics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrigenics SA filed Critical Hybrigenics SA
Priority to AU2002365517A priority Critical patent/AU2002365517A1/en
Publication of WO2003045990A2 publication Critical patent/WO2003045990A2/fr
Publication of WO2003045990A3 publication Critical patent/WO2003045990A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des interactions protéine-protéine impliquées dans des troubles et/ou des maladies associés au facteur de croissance transformant β. Elle concerne plus spécifiquement des complexes de polypeptides ou des polynucléotides codant pour ces polypeptides, des fragments des polypeptides, et des anticorps dirigés contre les complexes. Elle concerne aussi des domaines d'interaction sélectionnés (SID®) identifiés grâce aux interactions protéine-protéine, des procédés de criblage de médicaments concernant des principes qui modulent l'interaction de protéines, et des compositions pharmaceutiques pouvant moduler les interactions protéine-protéine.
PCT/EP2002/013866 2001-11-26 2002-11-26 Interactions proteine-proteine impliquant une signalisation du facteur de croissance transformant $g(b) ou des signaux de transduction d'elements de la famille des facteurs transformants $g(b) Ceased WO2003045990A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002365517A AU2002365517A1 (en) 2001-11-26 2002-11-26 Protein-protein interactions involving transforming growth factor beta signalling

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US33334801P 2001-11-26 2001-11-26
US60/333,348 2001-11-26
US38453702P 2002-05-31 2002-05-31
US60/384,537 2002-05-31
US42247102P 2002-10-30 2002-10-30
US60/422,471 2002-10-30

Publications (2)

Publication Number Publication Date
WO2003045990A2 WO2003045990A2 (fr) 2003-06-05
WO2003045990A3 true WO2003045990A3 (fr) 2004-04-01

Family

ID=27406912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/013866 Ceased WO2003045990A2 (fr) 2001-11-26 2002-11-26 Interactions proteine-proteine impliquant une signalisation du facteur de croissance transformant $g(b) ou des signaux de transduction d'elements de la famille des facteurs transformants $g(b)

Country Status (2)

Country Link
AU (1) AU2002365517A1 (fr)
WO (1) WO2003045990A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
USRE44437E1 (en) 2003-04-01 2013-08-13 Monogram Biosciences, Inc. Methods for detecting receptor complexes comprising PI3K

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059702A1 (en) * 2003-06-20 2007-03-15 Erich Wanker Disease related protein network
WO2005037071A2 (fr) 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Analyse de la voie de signalisation de la tyrosine kinase de recepteur pour diagnostic et therapie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053830A1 (fr) * 1997-05-28 1998-12-03 President And Fellows Of Harvard College PROCEDE ET REACTIFS PERMETTANT DE MODULER L'EMISSION DE SIGNAUX PAR LA SUPERFAMILLE DU TGF-$g(b)
WO1998055512A2 (fr) * 1997-06-02 1998-12-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Polypeptides a interaction avec smad et leur utilisation
WO2001064834A2 (fr) * 2000-02-28 2001-09-07 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053830A1 (fr) * 1997-05-28 1998-12-03 President And Fellows Of Harvard College PROCEDE ET REACTIFS PERMETTANT DE MODULER L'EMISSION DE SIGNAUX PAR LA SUPERFAMILLE DU TGF-$g(b)
WO1998055512A2 (fr) * 1997-06-02 1998-12-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Polypeptides a interaction avec smad et leur utilisation
WO2001064834A2 (fr) * 2000-02-28 2001-09-07 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIAO KAI ET AL: "Identification of mZnf8, a mouse Kruppel-like transcriptional repressor, as a novel nuclear interaction partner of Smad1.", MOLECULAR AND CELLULAR BIOLOGY, vol. 22, no. 21, November 2002 (2002-11-01), November, 2002, pages 7633 - 7644, XP002251797, ISSN: 0270-7306 *
LABBE E ET AL: "SMAD2 AND SMAD3 POSITIVELY AND NEGATIVELY REGULATE TGFBETA- DEPENDENT TRANSCRIPTION THROUGH THE FORKHEAD DNA-BINDING PROTEIN FAST2", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 2, no. 1, July 1998 (1998-07-01), pages 109 - 120, XP000857311, ISSN: 1097-2765 *
MASSAGUE J ET AL: "TGF-BETA SIGNALLING THROUGH THE SMAD PATHWAY", TRENDS IN CELL BIOLOGY, ELSEVIER SCIENCE LTD, XX, May 1997 (1997-05-01), pages 187 - 192, XP002911610, ISSN: 0962-8924 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
USRE44437E1 (en) 2003-04-01 2013-08-13 Monogram Biosciences, Inc. Methods for detecting receptor complexes comprising PI3K

Also Published As

Publication number Publication date
AU2002365517A8 (en) 2003-06-10
AU2002365517A1 (en) 2003-06-10
WO2003045990A2 (fr) 2003-06-05

Similar Documents

Publication Publication Date Title
WO2002057303A3 (fr) Interactions proteine-proteine entre des polypeptides shigella flexneri et des polypeptides de mammiferes
WO2002086122A3 (fr) Interactions proteine-proteine intensifiees dans des cellules adipeuses
WO2003046176A3 (fr) Interactions entre proteines dans le vih
AU2002305450A1 (en) Proteomimetic compounds and methods
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
MXPA05012316A (es) Peptidos novedosos que se unen al receptor de la eritropoyetina.
WO2005095457A3 (fr) Immunoglobulines
SG135917A1 (en) Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
WO2003031462A3 (fr) Blocage de la croissance axonale induit par le recepteur nogo
DE60034957D1 (de) Zusammensetungen und verfahren zur modulation von apoptose in cellen, die proteine der bc1-2-familie exprimieren
WO2003076592A3 (fr) Nouvelle methode d'administration et de synthese intracellulaire de molecules sirna
WO2007098198A3 (fr) Modulation de formation d'os
WO2003008454A3 (fr) Proteine de fusion, glycoproteine vi
GEP20094629B (en) Nogo receptor binding protein
WO2002065134A3 (fr) Procedes et agents de criblage
HUP0402496A2 (hu) Módosított polipeptidek
WO2002086076A3 (fr) Polynucleotides et polypeptides associes au chemin nf-kb
WO2002053726A3 (fr) Interactions proteine-proteine dans des cellules adipeuses
WO2002090544A3 (fr) Interactions proteine-proteine de cellules adipocytes (3)
WO2003045990A3 (fr) Interactions proteine-proteine impliquant une signalisation du facteur de croissance transformant $g(b) ou des signaux de transduction d'elements de la famille des facteurs transformants $g(b)
WO2006019982A3 (fr) Composes modulateurs de pin1 et leurs procedes d'utilisation
WO2003026700A3 (fr) Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
WO2002066501A3 (fr) INTERACTIONS PROTÉINE-PROTÉINE CHEZ $i(HELICOBACTER PILORI)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP